Atlas Trials

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

Clinical trial NCT02125240 · UNKNOWN

Trial details

NCT number
NCT02125240
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
EGFR Positive Non-small Cell Lung CancerAdenocarcinoma
Start date
2014-09-01
Primary completion
2018-12-01
Enrollment
124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.